Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Sandu Pharmaceutical
|
Lasa Supergenerics
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
65.41 % | 3.94 % | -8.32 % |
|
5yr average Equity Multiplier
|
-11.28 | 1.34 | 1.44 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 1.27 | 0.77 |
|
5yr Avg Net Profit Margin
|
0.0 | 2.31 % | -8.22 % |
|
Price to Book
|
1.95 | 1.12 | 0.59 |
|
P/E
|
0.0 | 30.11 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 27.73 Days | 11.27 Days |
|
Inventory Days
|
0.0 | 71.51 Days | 46.83 Days |
|
Days Receivable
|
0.0 | 26.2 Days | 10.61 Days |
|
Days Payable
|
0.0 | 79.23 Days | 83.41 Days |
|
5yr Average Interest Coverage Ratio
|
-836.53 | 28.27 | -18.91 |
|
5yr Avg ROCE
|
64.57 % | 5.77 % | 1.03 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 3.87 % | 9.99 % |
|
5 yr average Debt to Equity
|
-6.16 | 0.0 | 0.2 |
|
5yr CAGR Net Profit
|
65.28 % | -1.69 % | n/a |
|
5yr Average Return on Assets
|
-21.32 % | 2.94 % | -5.59 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 42.9 % | 53.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 20.66 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -7.53 % | 9.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Sandu Pharmaceutical
|
Lasa Supergenerics
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|